Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Barclays

Barclays began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Wednesday morning. The brokerage issued an equal weight rating and a $20.00 target price on the biotechnology company’s stock.

Several other equities research analysts also recently issued reports on SRPT. Wells Fargo & Company cut their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Royal Bank Of Canada raised their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 8th. Wedbush increased their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Finally, Wall Street Zen lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Nine analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $33.84.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $21.31 on Wednesday. The stock has a market capitalization of $2.23 billion, a PE ratio of -7.08, a price-to-earnings-growth ratio of 0.55 and a beta of 0.48. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $120.05. The stock has a 50 day moving average price of $21.41 and a 200 day moving average price of $19.87. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The company’s quarterly revenue was down 14.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 EPS. Analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. The trade was a 6.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently modified their holdings of the stock. Arizona State Retirement System increased its stake in Sarepta Therapeutics by 5.9% in the fourth quarter. Arizona State Retirement System now owns 27,701 shares of the biotechnology company’s stock valued at $596,000 after purchasing an additional 1,536 shares in the last quarter. M&T Bank Corp bought a new position in Sarepta Therapeutics in the 4th quarter valued at about $1,794,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Sarepta Therapeutics by 28.5% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 58,366 shares of the biotechnology company’s stock valued at $1,255,000 after purchasing an additional 12,948 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Sarepta Therapeutics by 10.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,454 shares of the biotechnology company’s stock worth $655,000 after purchasing an additional 2,954 shares in the last quarter. Finally, Krilogy Financial LLC raised its stake in shares of Sarepta Therapeutics by 164.7% in the fourth quarter. Krilogy Financial LLC now owns 27,982 shares of the biotechnology company’s stock worth $638,000 after purchasing an additional 17,409 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Three-year EMBARK topline results show sustained motor gains and slower disease progression for ELEVIDYS in Duchenne muscular dystrophy, supporting the therapy’s long-term value and lifting investor sentiment. SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
• Positive Sentiment: An analyst upgrade and bullish note prompted a sharp intraday jump (reports of ~13.9% move), reflecting short-term momentum from favorable coverage. Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 13.9% After Analyst Upgrade
• Neutral Sentiment: Coverage roundup pieces discuss the healthcare peer group and provide broader analyst context but don’t add new company-specific catalysts. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Several write-ups reassess valuation after recent short-term momentum — useful for longer‑term investors but not an immediate catalyst. Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Short-Term Share Price Momentum
• Negative Sentiment: Barclays initiated coverage with an “equal weight” rating and a $20.00 price target, which is below the current level and signals limited upside from here. (No link provided)
• Negative Sentiment: HC Wainwright reaffirmed a sell rating, keeping downside sentiment from some institutional analysts. Benzinga Coverage
• Negative Sentiment: Citi reiterated a bearish view — citing safety uncertainty and label risk around ELEVIDYS — and maintained a sell/high-risk stance, which contributes to negative near-term sentiment. Sarepta Therapeutics: Safety Uncertainty and Label Risk Overshadow Elevidys Data

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.